Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Rat LAG3 /CD223 Protein, 100µg  

Recombinant Rat LAG3 /CD223 Protein, 100µg

Recombinant Rat LAG3 /CD223 Protein (Rat LAG3 / CD223) Gly 24 - Leu 442 was produced in human 293 cells (HEK293), His Tag

Synonym: recombinant, rat, protein LAG3,CD223

More details

LA3-R52H5-100

Availability: within 7 days

377,00 €

Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens..

Source
Recombinant Rat LAG3, His Tag (LA3-R52H5) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Leu 442 (Accession # NP_997678).
Predicted N-terminus: Gly 24

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.6 kDa. The protein migrates as 55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort"
Lamas, Lassalle, Martel et al
Pathology (2023)
(2) "In vitro vascularized immunocompetent patient-derived model to test cancer therapies"
Lê, Deforges, Hua et al
iScience (2023) 26 (10), 108094
(3) "The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial"
Luke, Patel, Blumenschein et al
Nat Med (2023)
Showing 1-3 of 1488 papers.